From lab to patient: Optimising oncology formulations with purified excipients

Join us for an exclusive webinar on Tuesday 25 June 2024 to discover the impact of highly purified, Super Refined™ excipients on the stability and performance of several well-known small molecule chemotherapeutic formulations.

The challenge:
Degradation and instability in chemotherapeutics can lead to extended development timelines, regulatory challenges, and compromised product efficacy. This delays lifesaving treatments for those who need it most—the patients.

Join to learn:
During this webinar, we will evaluate stability data of several small molecule drugs for cancer belonging to the microtubule inhibitor drug class (docetaxel, paclitaxel), topoisomerase inhibitors (etoposide), as well as hormone-based oncology drugs (fulvestrant). We will show you how we can optimise oncological drug delivery resulting in long-term formulation stability, extended drug shelf life, and ultimately improved drug performance and efficacy.

Key topics:

Presentation on our offerings for small molecule API delivery, with a focus on the parenteral administration route and the role of purity.
Evaluation of the stability of several well-known small molecule APIs for oncology formulated with Super Refined™ versus standard, compendial-grade excipients.
Preview of our offerings for large molecule therapy development for oncology, such as mAbs and nucleic acid-based cancer therapies, from upstream to downstream biomanufacturing.

Who should attend?
This webinar will benefit professionals across all stages of oncology drug development: formulation scientists, research scientists, drug product developers and pharmaceutical engineers.

Together, let's unlock new solutions to your most pressing challenges in oncology drug development and redefine the boundaries of what is possible in the fight against cancer.

Jessica is a global Technical Marketing Lead for Croda Pharma’s Small Molecule and Protein Delivery platforms. Jessica holds a Bachelor of Science in Biochemistry and Nutritional Sciences from Rutgers University, and an MBA in Pharmaceutical Management and Marketing. Her undergraduate research focused on identifying therapeutic targets for breast and ovarian cancer in overexpression systems. In her current role, Jessica leads cross functional teams to support new product development, driving teams to successful commercial global launches.

James has over 15 years’ experience focusing on the formulation sector, and holds his MChem from University of Hull. Whilst at Croda, he has worked on formulating with Croda’s current range of surfactants, leading new surfactant development teams and focusing on formulation science to develop high performance, sustainable surfactants. Over the last 10 years James has focused on understanding and development of excipients for the pharmaceutical sector, with particular interest in the role of excipient type and quality on the stability and delivery of drugs of differing modalities in numerous dosage forms.

Select all

From Lab to Patient: Optimising Oncology Formulations with Purified Excipients (EMEA/APAC) 25/06/24, 9:00 BST Available On Demand

From Lab to Patient: Optimising Oncology Formulations with Purified Excipients (NAMER/LATAM) 25/06/24, 10:00 CST Available On Demand

Please select at least one event

First name

Please provide your first name

Last name

Please provide your last name

Please provide an email address

Unfortunately, you are not able to register with that email address. Please get in touch using our contact form and one of our team will assist you.

Company

Please provide your company name

Job title

Department

Country

County/Region

Phone

Please provide a valid phone

I have read and understood Croda’s privacy policy

Please confirm you have read and understood Croda’s privacy policy

Would you like to receive updates on our products, events and other marketing communications from Croda?

Explore related resources:

Promising new results for metastatic prostate cancer vaccine

test tube and flask in medical chemistry

Croda’s response to Sustainable Markets Initiative for supplier sustainability targets

“Close the Care Gap” – World Cancer Day 2024

Excipients for Small Molecule Delivery

From Lab to Patient: Optimising Oncology Formulations with Purified Excipients

Speakers

Thank you for registering!

Explore related resources: